Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)-Reference-Cited by-同舟云学术

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Published:2019-12-01 Issue:10 Volume:35 Page:542-550
ISSN:1080-7683
Container-title:Journal of Ocular Pharmacology and Therapeutics
language:en
Short-container-title:Journal of Ocular Pharmacology and Therapeutics

Author:

Aihara Makoto¹,Lu Fenghe²,Kawata Hisashi³,Tanaka Yuki³,Yamamura Kenzo⁴,Odani-Kawabata Noriko²³,Shams Naveed K.²³

Affiliation:

1. Department of Ophthalmology, University of Tokyo, Bunkyo-ku, Japan.

2. Santen, Inc., Emeryville, California.

3. Santen Pharmaceutical Co., Ltd., Osaka, Japan.

4. Santen Pharmaceutical Co., Ltd., Ikoma, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmacology,Ophthalmology

Link

https://www.liebertpub.com/doi/pdf/10.1089/jop.2019.0044

Reference36 articles.

1. Glaucoma

2. Update on the Medical Treatment of Primary Open-Angle Glaucoma

3. Netarsudil Ophthalmic Solution 0.02%: First Global Approval

4. Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent

5. The Ocular Hypertension Treatment Study

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug;Current Opinion in Pharmacology;2024-02

2. Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis;Journal of Ocular Pharmacology and Therapeutics;2023-12-01

3. Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients;Pharmaceuticals;2023-05-26

4. FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma;Experimental Eye Research;2023-04

5. Newly or switching effect of a selective EP2 agonist on intraocular pressure in Japanese patients with open-angle glaucoma;Japanese Journal of Ophthalmology;2022-07-30